Notably, activation of BTK signaling is an essential feature of some B-cell malignancies such as chronic lymphoid leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM), and inhibitors of BTK (i.e., ibrutinib) are standard of care therapies for these cancers. This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.